Even After Rising 18% This Past Week, Akebia Therapeutics (NASDAQ:AKBA) Shareholders Are Still Down 74% Over the Past Five Years

Simply Wall StJan 18 08:56 ET

Akebia Therapeutics Analyst Ratings

BenzingaJan 14 12:18 ET · Ratings

H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $7.5

Moomoo NewsJan 14 11:32 ET · Ratings

Akebia Announced Near 100% U.S. Dialysis Coverage For Vafseo, Vafseo Shipments Commence, Phase 3 Trial For Late-Stage Non-Dialysis CKD Patients Planned for Mid-2025

BenzingaJan 13 08:26 ET

Akebia Therapeutics Announces Multiple Positive Business Updates

PR NewswireJan 13 08:00 ET

Express News | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersDec 3, 2024 16:05 ET